- Question from enjoyful: Are there any promising, new therapies for metastatic, ER+ cancers?
- Answers - Kathy D. Miller, M.D. There was no specifically new hormonal therapy, but there was important information about fulvestrant or Faslodex. This medication has typically been given as an injection in the muscle once a month and has been effective in women with ER+ metastatic disease. We learned this year that using slightly higher doses of this drug makes it more effective, but does not increase the side effects. There was also an important study looking at combining fulvestrant with an aromatase inhibitor such as Arimidex (chemical name: anastrozole). In that study, the combination was not more effective than using the drugs by themselves. So while there wasn't a new therapy specifically for women with ER+ disease, we did learn important information about how to use these existing therapies more effectively.
The Ask-the-Expert Online Conference called Updates From the 2009 San Antonio Breast Cancer Symposium featured Kathy Miller, M.D. and Kristin Brill, M.D., F.A.C.S. answering your questions about the latest updates on breast cancer risk, screening techniques, treatment options, and more.
Editor's Note: This conference took place in December 2009.
The materials presented in these conferences do not necessarily reflect the views of Breastcancer.org. A qualified healthcare professional should be consulted before using any therapeutic product or regimen discussed. All readers should verify all information and data before employing any therapies described here.
A production of LiveWorld, Inc.
Copyright 2010. All rights reserved.